Increased EFG-and PDGFα-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis

Human Molecular Genetics

Volumn 19, Issue 9, 2010, Pages 1678-1689

  Miraoui, Hichem ^a,b   Ringe, Jochen ^c   Häupl, Thomas ^c   Marie, Pierre J ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE C ALPHA; SPROUTY PROTEIN; SPROUTY2 PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FGFR2 PROTEIN, HUMAN; PRIMER DNA;

ACROCEPHALOSYNDACTYLY; ARTICLE; BONE MINERALIZATION; CELL DAMAGE; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; FETUS; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR MECHANICS; OSTEOBLAST; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; MICROARRAY ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACROCEPHALOSYNDACTYLIA; BLOTTING, WESTERN; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FETUS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; MUTATION; OSTEOBLASTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 77952529135     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq045     Document Type: Article

References (58)

1. Opperman, L.A. (2000) Cranial sutures as intramembranous bone growth sites. Dev. Dyn., 219, 472-485.
2. Cohen, M.M. Jr. (2005) Perspectives on craniosynostosis. Am. J. Med. Genet., 136, 313-326.
3. Wilkie, A.O. (1997) Craniosynostosis: genes and mechanisms. Hum. Mol. Genet., 6, 1647-1656.
4. Ornitz, D.M. and Marie, P.J. (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev., 16, 1446-1465.
5. Dailey, L., Ambrosetti, D., Mansukhani, A. and Basilico, C. (2005) Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev., 16, 233-247.
6. Jabs, E.W. (1998) Toward understanding the pathogenesis of craniosynostosis through clinical and molecular correlates. Clin. Genet., 53, 79-86.
7. Wilkie, A.O. (2005) Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth. Factor. Rev., 16, 187-203.
8. Anderson, J., Burns, H.D., Enriquez-Harris, P., Wilkie, A.O.M. and Heath, J.K. (1998) Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum. Mol. Genet., 7, 1475-1483.
9. Yu, K., Herr, A.B., Waksman, G. and Ornitz, D.M. (2000) Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc. Nat. Acad. Sci. USA, 97, 14536-14541.
10. Yu, K. and Ornitz, D.M. (2000) Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes. Proc. Natl Acad. Sci. USA, 98, 3641-3643.
11. Ibrahimi, O.A., Eliseenkova, A.V., Plotnikov, A.N., Yu, K., Ornitz, D.M. and Mohammadi, M. (2001) Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc. Natl Acad. Sci. USA, 98, 7182-7187.
12. Marie, P.J., Kaabeche, K. and Guenou, H. (2008) Roles of FGFR2 and twist in human craniosynostosis: insights from genetic mutations in cranial osteoblasts. Front. Oral Biol., 12, 144-159.
13. Kim, H.J., Lee, M.H., Park, H.S., Park, M.H., Lee, S.W., Kim, S.Y., Choi, J.Y., Shin, H.I., Kim, H.J. and Ryoo, H.M. (2003) Erk pathway and activator protein 1 play crucial roles in FGF2-stimulated premature cranial suture closure. Dev. Dyn., 227, 335-346.
14. Mansukhani, A., Ambrosetti, D., Holmes, G., Cornivelli, L. and Basilico, C. (2005) Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J. Cell Biol. 168, 1065-1076.
15. Shukla, V., Coumoul, X., Wang, R.H., Kim, H.S. and Deng, C.X. (2007) RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat. Genet., 39, 1145-1150.
16. Lomri, A., Lemonnier, J., Hott, M., de Perseval, N., Lajeunie, E., Munnich, A., Renier, D. and Marie, P.J. (1998) Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor-2 mutations in Apert syndrome. J. Clin. Invest., 101, 1310-1317.
17. Lomri, A., Lemonnier, J., Delannoy, P. and Marie, P.J. (2001) Identification of genes induced by the Ser252Trp FGFR-2 Apert mutation in osteoblasts using atlas human expression arrays: evidence for increased expression of PKCa, IL-1a and RhoA GTPase. J. Bone Miner. Res., 16, 705-712.
18. Lemonnier, J., Hay, E., Delannoy, P., Lomri, A., Modrowski, D., Caverzasio, J. and Marie, P.J. (2001) Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J. Bone Miner. Res., 16, 832-845.
19. Kaabeche, K., Lemonnier, J., Le Mée, S., Caverzasio, J. and Marie, P.J. (2004) Cbl-mediated degradation of Lyn and Fyn induced by constitutive FGFR-2 activation supports osteoblast differentiation. J. Biol. Chem., 279, 36259-36267.
20. Häupl, T., Yahyawi, M., Lübke, C., Ringe, J., Rohrlach, T., Burmester, G.R., Sittinger, M. and Kaps, C. (2007) Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J. Biomol. Screen., 12, 328-340.
21. Schlessinger, J. (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science, 306, 1506-1507.
22. Martineau-Doizé, B., Lai, W.H., Warshawsky, H. and Bergeron, J.J. (1988) In vivo demonstration of cell types in bone that harbor epidermal growth factor receptors. Endocrinology, 123, 841-858.
23. Centrella, M., McCarthy, T.L., Kusmik, W.F. and Canalis, E. (1992) Isoform-specific regulation of platelet-derived growth factor activity and binding in osteoblast-enriched cultures from fetal rat bone. J. Clin. Invest., 89, 1076-1084.
24. Eswarakumar, V.P., Lax, I. and Schlessinger, J. (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev., 16, 139-149.
25. Kawagishi, J., Kumabe, T., Yoshimoto, T. and Yamamoto, T. (1995) Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRα. Genomics, 30, 224-232.
26. Johnson, A.C., Murphy, B.A., Matelis, C.M., Rubinstein, Y., Piebenga, E.C., Akers, L.M., Neta, G., Vinson, C. and Birrer, M. (2000) Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol. Med., 6, 17-27.
27. Glass, D.A. 2nd and Karsenty, G. (2006) Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr. Top. Dev. Biol., 73, 43-84.
28. Baron, R., Rawadi, G. and Roman-Roman, S. (2006) Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol., 76, 103-127.
29. Logan, C.Y. and Nusse, R. (2004) The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol, 20, 781-810.
30. Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell, 103, 211-225.
31. Thien, C.B. and Langdon, W.Y. (2001) Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol, 2, 294-307.
32. Tsygankov, A.Y., Teckchandani, A.M., Feshchenko, E.A. and Swaminathan, G. (2001) Beyond the RING: CBL proteins as multivalent adapters. Oncogene, 20, 6382-6402.
33. Levkowitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W.Y., Beguinot, L., Geiger, B. and Yarden, Y. (1998) c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev., 12, 3663-3674.
34. Miyake, S., Lupher, M.L. Jr, Druker, B. and Band, H. (1998) The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc. Natl Acad. Sci. USA, 95, 7927-7932.
35. Joazeiro, C.A., Wing, S.S., Huang, H., Leverson, J.D., Hunter, T. and Liu, Y.C. (1999) The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science, 286, 309-312.
36. Mason, J.M., Morrison, D.J., Basson, M.A. and Licht, J.D. (2006) Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol., 16, 45-54.
37. Wong, E.S. and Guy, G.R. (2006) Regulator of epidermal growth factor signaling: Sprouty. Methods Mol. Biol., 327, 61-83.
38. Fong, C.W., Leong, H.F., Wong, E.S., Lim, J., Yusoff, P. and Guy, G.R. (2003) Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. J. Biol. Chem., 278, 33456-33464
39. Edwin, F. and Patel, T.B. (2008) A novel role of Sprouty 2 in regulating cellular apoptosis. J. Biol. Chem., 283, 3181-3190.
40. Centrella, M., McCarthy, T.L. and Canalis, E. (1989) Platelet-derived growth factor enhances deoxyribonucleic acid and collagen synthesis in osteoblast-enriched cultures from fetal rat parietal bone. Endocrinology, 125, 13-19.
41. Yu, X., Hsieh, S.C., Bao, W. and Graves, D.T. (1997) Temporal expression of PDGF receptors and PDGF regulatory effects on osteoblastic cells in mineralizing cultures. Am. J. Physiol., 272, C1709-C1716.
42. O'Sullivan, S., Naot, D., Callon, K., Porteous, F., Horne, A., Wattie, D., Watson, M., Cornish, J., Browett, P. and Grey, A. (2007) Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J. Bone Miner. Res., 22, 1679-1689.
43. Fitter, S., Dewar, A.L., Kostakis, P., To, L.B., Hughes, T.P., Roberts, M.M., Lynch, K., Vernon-Roberts, B. and Zannettino, A.C. (2008) Long-term imatinib therapy promotes bone formation in CML patients. Blood, 111, 2538-2547.
44. Marie, P.J., Hott, M. and Perheentupa, J. (1990) Effects of epidermal growth factor on bone formation and resorption in vivo. Am. J. Physiol., 258, E275-E281.
45. Mitlak, B.H., Finkelman, R.D., Hill, E.L., Li, J., Martin, B., Smith, T., D'Andrea, M., Antoniades, H.N. and Lynch, S.E. (1996) The effect of systemically administered PDGF-BB on the rodent skeleton. J. Bone Miner. Res., 11, 238-247.
46. Schneider, M.R., Mayer-Roenne, B., Dahlhoff, M., Proell, V., Weber, K., Wolf, E. and Erben, R.G. (2009) High cortical bone mass phenotype in betacellulin transgenic mice is EGFR dependent. J. Bone Miner. Res., 24, 455-467.
47. Moenning, A., Jäger, R., Egert, A., Kress, W., Wardelmann, E. and Schorle, H. (2009) Sustained platelet-derived growth factor receptor alpha signaling in osteoblasts results in craniosynostosis by overactivating the phospholipase C-gamma pathway. Mol. Cell. Biol., 29, 881-891.
48. Bonello, M.R. and Khachigian, L.M. (2004) Fibroblast growth factor-2 represses platelet-derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter. [Erratum (2005) J. Biol. Chem. 280, 1704] J. Biol. Chem, 279, 2377-2382.
49. Angel, P. and Karin, M. (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta, 1072, 129-157.
50. Wagner, E.F. (2002) Functions of AP1 (Fos/Jun) in bone development. Ann. Rheum. Dis., 61 (Suppl. 2), ii40-ii42.
51. Dikic, I. and Giordano, S. (2003) Negative receptor signalling. Curr. Opin. Cell Biol., 15, 128-135.
52. Wong, A., Lamothe, B., Lee, A., Schlessinger, J. and Lax, I. (2002) FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc. Natl Acad. Sci. USA, 99, 6684-6689.
53. Hanafusa, H., Torii, S., Yasunaga, T. and Nishida, E. (2002) Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol., 4, 850-858.
54. Wong, E.S., Fong, C.W., Lim, J., Yusoff, P., Low, B.C., Langdon, W.Y. and Guy, G.R. (2002) Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J., 21, 4796-4808.
55. Eswarakumar, V.P., Ozcan, F., Lew, E.D., Bae, J.H., Tomé, F., Booth, C.J., Adams, D.J., Lax, I. and Schlessinger, J. (2006) Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proc. Natl Acad. Sci. USA, 103, 18603-18608.
56. Perlyn, C.A., Morriss-Kay, G., Darvann, T., Tenenbaum, M. and Ornitz, D.M. (2006) A model for the pharmacological treatment of crouzon syndrome. Neurosurgery, 59, 210-215.
57. Wilkie, A.O. (2007) Cancer drugs to treat birth defects. Nat. Genet., 39, 1057-1059.
58. Miraoui, H., Oudina, K., Petite, H., Tanimoto, Y., Moriyama, K. and Marie, P.J. (2009) Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J. Biol. Chem., 284, 4897-4904.